AN2 Therapeutics | 10-Q: Quarterly report
AN2 Therapeutics | 8-K: AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics | 10-K/A: Annual report (Amendment)
AN2 Therapeutics | ARS: Annual Report to Security Holders
AN2 Therapeutics | DEFA14A: Others
AN2 Therapeutics | DEF 14A: Definitive information statements
AN2 Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-James N. Topper(5.0%),Patrick J. Heron(5.0%), etc.
AN2 Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
AN2 Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
AN2 Therapeutics | 10-K: Annual report
AN2 Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Eckburg Paul
AN2 Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Day Lucy
AN2 Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Eizen Joshua M
AN2 Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Easom Eric
AN2 Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Chanda Sanjay
AN2 Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Krause Kevin Michael
AN2 Therapeutics | 8-K: AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Day Lucy
AN2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Eizen Joshua M
AN2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Krause Kevin Michael
No Data